Cellectar Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CLRB$1.28+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporation by Reference | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ExhibitNo. | | Description | | Filed withthisForm 10-Q | | Form | | Filing Date | | ExhibitNo. |
| | | | | | | | | | | |
| 4.1 | | Form of Pre-Funded Common Stock Purchase Warrant | | | | 8-K | | May 8, 2026 | | 4.1 |
| 4.2 | | Form of Series A Common Stock Purchase Warrant | | | | 8-K | | May 8, 2026 | | 4.2 |
| 4.3 | | Form of Series B Common Stock Purchase Warrant | | | | 8-K | | May 8, 2026 | | 4.3 |
| 4.4 | | Form of Series C Common Stock Purchase Warrant | | | | 8-K | | May 8, 2026 | | 4.4 |
| 4.5 | | Form of Placement Agent Warrant | | | | 8-K | | May 8, 2026 | | 4.5 |
| 10.1 | | Form of Securities Purchase Agreement, dated May 4, 2026, by and among the Company and the institutional investors identified on the signatures pages thereto | | | | 8-K | | May 8, 2026 | | 10.1 |
| 10.2 | | Form of Securities Purchase Agreement, dated May 4, 2026, by and among the Company and the members of management identified on the signatures pages thereto | | | | 8-K | | May 8, 2026 | | 10.2 |
| 10.3 | | Form of Registration Rights Agreement, dated May 4, 2026, by and among the Company and the investors identified on the signature pages thereto | | | | 8-K | | May 8, 2026 | | 10.3 |
| 10.4 | | Form of Placement Agency Agreement, dated May 4, 2026, by and between the Company and Ladenburg Thalmann & Co. Inc. | | | | 8-K | | May 8, 2026 | | 10.4 |
| 10.5 | | Letter Agreement, dated May 4, 2026, by and between the Company and Nantahala Capital Management, LLC | | | | 8-K | | May 8, 2026 | | 10.5 |
| 10.6 | | Cellectar Biosciences, Inc. 2021 Stock Incentive Plan, as Amended | | | | 8-K | | July 10, 2026 | | 10.1 |
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 101 | Interactive Data Files | X | ||||||||
| 104 | | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit). | | X | | | | | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CELLECTAR BIOSCIENCES, INC. | ||
| Date: August 13, 2026 | By: | /s/ James V. Caruso |
|---|---|---|
| James V. Caruso | ||
| President and Chief Executive Officer | ||
| | | (Principal Executive Officer) |
| | | |
| Date: August 13, 2026 | By: | /s/ Chad J. Kolean |
| | | Chad J. Kolean |
| | | Chief Financial Officer |
| | | (Principal Financial and Accounting Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.